ERLEADA (apalutamide)
SELF ADMINISTRATION
Indications for Prior Authorization:
- Treatment of patients with non-metastatic castration-resistant prostate cancer (NM-CRPC)
Patients must meet the following criteria for the indication(s) above:
- Diagnosis of non-metastatic, castration-resistant prostate cancer (NM-CRPC), AND
- Prescribed by or in consultation with an oncologist or urologist, AND
- Patient will receive a gonadotropin-releasing hormone (GnRH) analog concurrently or has had bilateral orchiectomy
Dosing:
- 240 mg (four 60mg tablets) once daily
- Bone support should be used in patients receiving Erleada
Approval:
- 1 year
Last review date: April 23, 2019